Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
企業コードMREO
会社名Mereo BioPharma Group PLC
上場日Jun 09, 2016
設立日2015
最高経営責任者「CEO」Dr. Denise V. Scots-Knight, Ph.D.
従業員数36
証券種類Depository Receipt
決算期末Jun 09
本社所在地One Cavendish Place
都市LONDON
証券取引所NASDAQ Capital Market Consolidated
国United Kingdom
郵便番号W1G0QF
電話番号443330237300
ウェブサイトhttps://www.mereobiopharma.com/
企業コードMREO
上場日Jun 09, 2016
設立日2015
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし